Noch keine Produkte im Warenkorb.
Ihre Vorteile:
versandkostenfreie Lieferung
aller Studien u. Marktanalysen
oder per Kreditkarte
Bestell- und Beratungshotline
Gerne helfen wir Ihnen kostenfrei bei der Recherche nach Studien und Marktanalysen:
Tel.: +49 (0)221 168 262 42
E-Mail: service[at]marktforschung.de
Aktuelle Meldungen aus dem Ressort Studien / Marktanalysen:
15.07.10 Kooperation im Vertrieb – wer nicht kooperiert, verliert!
Köln - Wer viel Zeit und Geld hat, der wird in der Wirtschaft alles möglichst alleine machen...
28.06.10 Marktstudie Augenoptik: Die Augenoptikbranche stemmt sich erfolgreich gegen die Wirtschaftskrise
Neuwied - Der deutsche Optikmarkt hat sich zum normalen Konsumgütermarkt entwickelt und seinen...
17.06.10 Marktstudie Elektro-Kleingeräte: Branche im Aufwind
Neuwied - 2009 erreichte der Markt für Elektro-Kleingeräte mit einem Plus von 3,3 Prozent auf 3,4...
Benutzer Anmeldung
Regelmäßig Informationen über neue Studien und Spezialangebote im Shop im kostenlosen E-Mail-Abo.
Mehr Infos? Hier klicken.
Hormone / Stoffwechsel
Studien / Marktanalysen aus der Kategorie Hormone / Stoffwechsel
| Titel | ||
|---|---|---|
Growth Hormone Deficiency (GHD) - Pipeline Analysis and Market Forecasts to 2016Von: GlobalData
|
5 / 2010 |
1.400,00 € ( 2.000,00 $) |
|
Growth Hormone Deficiency (GHD) - Pipeline Analysis and Market Forecasts to 2016 |
||
Cough, Cold and Allergy (hay Fever) Remedies - VietnamVon: Euromonitor
|
5 / 2010 |
675,00 € |
|
The number of people migrating to large cities like Hanoi, Danang, and Ho Chi Minh City continued to increase during 2009 and urban noise and air pollution is becoming and ever larger problem in Vietnam. Moreover, the population density in large cities such as Ho Chi Minh City is very high, causing traffic jams and high levels of smoke and dirt which are causing throat, lung, and nose related health problems. |
||
Growth Hormone Deficiency Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', Growth Hormone Deficiency Therapy Area Pipeline Report contains detailed information on the growth hormone deficiency drug pipeline. This report provides insight into the pipeline status of growth hormone deficiency drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Hormone Replacement Therapy Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', Hormone Replacement Therapy Therapy Area Pipeline Report contains detailed information on the hormone replacement therapy drug pipeline. This report provides insight into the pipeline status of hormone replacement therapy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Hyperthyroidism Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', Hyperthyroidism Therapy Area Pipeline Report contains detailed information on the hyperthyroidism drug pipeline. This report provides insight into the pipeline status of hyperthyroidism drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Hypogonadism Therapy Area Pipeline ReportVon: Life Science Analytics
|
4 / 2010 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', Hypogonadism Therapy Area Pipeline Report contains detailed information on the hypogonadism drug pipeline. This report provides insight into the pipeline status of hypogonadism drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Commercial Insight: Hormonal Contraceptives - Look beyond oral contraception for a competitive edgeVon: Datamonitor
|
10 / 2009 |
10.640,01 € ( 15.200,00 $) |
|
Introduction |
||
Hormonal Contraceptives Market ForecastVon: Datamonitor
|
10 / 2009 |
10.640,01 € ( 15.200,00 $) |
|
Introduction |
||
Forecast Insight: Attention-Deficit Hyperactivity Disorder - Shire to stay on top despite drug safety fears and generic competitionVon: Datamonitor
|
7 / 2009 |
10.640,01 € ( 15.200,00 $) |
|
Introduction |
||
Metabolic Endocrinology Growth Hormone DeficiencyVon: Life Science Analytics
|
4 / 2008 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', 'Metabolic Endocrinology Growth Hormone Deficiency ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Metabolic Endocrinology Hormone Replacement TherapyVon: Life Science Analytics
|
4 / 2008 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', 'Metabolic Endocrinology Hormone Replacement Therapy ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Metabolic Endocrinology HypercalcemiaVon: Life Science Analytics
|
4 / 2008 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', 'Metabolic Endocrinology Hypercalcemia ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Metabolic Endocrinology HypocalcemiaVon: Life Science Analytics
|
4 / 2008 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', 'Metabolic Endocrinology Hypocalcemia ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Metabolic Endocrinology HypogonadismVon: Life Science Analytics
|
4 / 2008 |
1.046,50 € ( 1.495,00 $) |
|
Life Science Analytics', 'Metabolic Endocrinology Hypogonadism ' contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area. |
||
Commercial and Pipeline Insight: HRT for Menopausal Symptoms – A new class restores an old marketVon: Datamonitor
|
4 / 2008 |
10.640,01 € ( 15.200,00 $) |
|
Introduction |
||
*Unser Angebot richtet sich an gewerbliche Kunden, daher sind alle Preise netto ausgewiesen.
In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%).
Der korrekte Gesamtendpreis wird Ihnen nach Angabe Ihrer Rechnungsadresse im weiteren Bestellablauf ausgewiesen.

